Wednesday, 29 August 2007

Trials of Nexavar liver cancer drug stopped early

Filed under: ,

Nexavar, a pharmaceutical drug designed to treat liver cancer, had a late-stage trial recently cut off and disbanded.

But, the reason is not what you think: the trial was ended because the results of patients using the drug were all so positive that a further continuation of the trial was not needed.

The trial (which was classified "Phase III" -- the 'final' stage) was conducted on over 200 patients in China, Korea and Taiwan. All patients took Nexavar and all were suffering from hepatocellular carcinoma -- the most common liver cancer.

Still, it's odd that any trials were ended due to excellent results. Even if that is so, shouldn't all drugs complete a start-to-finish trial period, regardless of success rate?

No comments: